Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vertex Pharmaceuticals Incorporated
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects (male and female) must be between the ages of 18 and 60 years at screening
Subjects must have genotype 1 Chronic Hepatitis C
Subjects must be treatment naïve
Subjects must have laboratory values at screening within limits as specified by the protocol
You may not be if
Evidence of cirrhosis
Female subjects who are pregnant or nursing or male subjects with a female partner of childbearing potential who is unwilling to adhere to the contraception requirements, is pregnant or nursing, or planning to become pregnant during the study
Any other cause of significant liver disease in addition to hepatitis C
Human immunodeficiency virus -1 or -2
Diagnosis of or suspected hepatocellular carcinoma
History of organ transplant, with the exception of corneal transplants and skin grafts
Clareo Health | A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
